A 73-year-old woman with osteoporosis

JAMA

Volumn 281, Issue 16, 1999, Pages 1531-1540

  Greenspan, Susan L ^b   Hartman, Erin E ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; CALCITONIN; CALCIUM CARBONATE; CALTRATE PLUS D; COLECALCIFEROL; COLLAGEN; ESTRADIOL; ESTROGEN; GESTAGEN; RALOXIFENE; UNCLASSIFIED DRUG; VITAMIN D;

AGED; ARTICLE; BONE DENSITY; CASE REPORT; DENSITOMETRY; EXERCISE; FEMALE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; ORAL DRUG ADMINISTRATION; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RISK FACTOR; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0344780796     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.281.16.1531     Document Type: Article

References (65)

1. Kanis JA, and the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368-381.
2. Melton LJ III, Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis? J Bone Miner Res. 1992;7:1005-1010.
3. Praemer A, Furner S, Rice DP. Costs of musculoskeletal conditions. In: Musculoskeletal Conditions in the United States. Park Ridge, III: American Academy of Orthopaedic Surgeons; 1992:143-170.
4. Melton LJ III, Riggs BL. Epidemiology of age-related fractures. In: Avioli LV, ed. The Osteoporotic Syndrome. New York, NY: Grune & Stratton; 1983:45-72.
5. Cummings SR, Black D. Should perimenopausal women be screened for osteoporosis? Ann Intern Med. 1986;104:817-823.
6. Riggs BL, Melton LJ III. Involutional osteoporosis. N Engl J Med. 1986;314: 1676-1686.
7. Ray NF, Chan JK, Thamer M, Melton LJ III. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res. 1997;12:24-35.
8. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age. J Bone Miner Res. 1994;9:1959-1965.
9. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med. 1998; 338:736-746.
10. Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-773.
11. Grisso JA, Kelsey JL, Strom BL, et al. Risk factors for falls as a cause of hip fracture in women. N Engl J Med. 1991;324:1326-1331.
12. Melton LJ, Chao EYS, Lane J. Biochemical aspects of fractures. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis and Management. New York, NY: Raven Press; 1988:111-131.
13. Greenspan SL, Myers ER, Maitland LA, Resnick NM, Hayes WC. Fall severity and bone mineral density as risk factors for hip fracture in ambulatory elderly. JAMA. 1994;271:128-133.
14. Physician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 1998:1-38.
15. Medicare coverage of and payments for bone mass measurements, 63 Federal Register 34321 (1998).
16. Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137.
17. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997;7:1-6.
18. Melton LJ III, Atkinson EJ, O'Fallon WM, Wahner HW, Riggs BL. Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res. 1993;8:1227-1233.
19. Cummings SR, Black DM, Nevitt MC, et al. Bone density at various sites for prediction of hip fractures. Lancet. 1993;341:72-75.
20. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
21. Diagnostic and therapeutic technology assessment: measurement of bone density with dual-energy x-ray absorptiometry. JAMA. 1992;267:286-294.
22. Baran DT, Faulkner KG, Genant HK, Miller PD, Pacifici R. Diagnosis and management of osteoporosis. Calcif Tissue Int. 1997;61:433-440.
23. Genant HK, Engelke K, Fuerst T, et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res. 1996;11:707-730.
24. Greenspan SL, Bouxsein ML, Melton ME, et al. Precision and discriminatory ability of calcaneal bone assessment technologies. J Bone Miner Res. 1997;12: 1303-1313.
25. Dawson-Hughes B, Dalial GE. Effect of radiographic abnormalities on rate of bone loss from the spine. Calcif Tissue Int. 1990;46:280-281.
26. Orwoll ES, Oviatt SK, Mann T. The impact of osteophytic and vascular calcifications on vertebral mineral density measurements in men. J Clin Endocrinol Metab. 1990;70:1202-1207
27. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.
28. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;337:670-676.
29. National Institutes of Health. Optimal Calcium Intake. Bethesda, Md: National Institutes of Health; 1994. NIH consensus statement 12:4.
30. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride. Washington, DC: National Academy Press; 1997.
31. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338:777-783.
32. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642.
33. Tinetti ME, Baker DI, McAvay G, et al. A multifactorial intervention to reduce the risk of falling among elderly people living in the community. N Engl J Med. 1994;331:821-827.
34. Col NF, Eckman MH, Karas RH, et al. Patient-specific decisions about hormone replacement therapy in postmenopausal women. JAMA. 1997;277:1140-1147.
35. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol. 1984;63:759-763.
36. Genant HK, Baylink DJ, Gallagher JC, et al. Effect of estrone sulfate on postmenopausal bone loss. Obstet Gynecol. 1990;76:579-584.
37. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Intern Med. 1987;106: 40-45.
38. Genant HK, Lucas H, Weiss S, et al, for the Estratab/Osteoporosis Study Group. Low-dose esterified estrogen therapy. Arch Intern Med. 1997;157:2609-2615.
39. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 1996;276:1389-1396.
40. Lufkin EG, Wahner HW, O'Fallon WM, et al. Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med. 1992;117:1-9.
41. Christiansen C, Riis BJ. 17 Beta-estradiol and continuous norethisterone. J Clin Endocrinol Metab. 1990;71:836-841.
42. Lindsay R, Tohme JF. Estrogen treatment of patients with osteoporosis. Obstet Gynecol. 1990;76:290-295.
43. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Ann Intern Med. 1995;122:9-16.
44. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348:1535-1541.
45. Liberman UA, Weiss SR, Broll J, et al. Effect of treatment with oral alendronate on bone mineral density and fracture incidence in postmenopausal osteoporosis. N Engl J Med. 1995;333:1437-1443.
46. Cummings SR, Black DM, Thompson DE, et al, for the Fracture Intervention Trial Research Group. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.
47. McClung M, Clemmesen B, Daifotis A, et al, for the Alendronate Osteoporosis Prevention Study Group. Alendronate prevents postmenopausal bone loss in women without osteoporosis. Ann Intern Med. 1998;128:253-261.
48. Overgaard K, Hansen MA, Jensen SB, Christiansen C. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. BMJ. 1992;305:556-561.
49. Stock JL, Avioli LV, Baylink DJ, et al, for the PROOF Study Group. Calcitoninsalmon nasal spray reduces the incidence of new vertebral fractures in postmenopausal women [abstract]. J Bone Miner Res. 1997;12(suppl 1):S149.
50. Lyritis GP, Tsakalakos N, Magiasis B, Karachalios T, Yiatzides A, Tsekoura M. Analgesic effect of salmon calcitonin in osteoporotic vertebral fractures: a double-blind placebo-controlled clinical study. Calcif Tissue Int. 1991;49:369-372.
51. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med. 1997;337:1641-1647.
52. Ensrud K, Black D, Recker R, et al, for the MORE Study Group. The effect of 2 and 3 years of raloxifene on vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [abstract]. Bone. 1998;23(suppl):S174.
53. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-79.
54. Storm T, Thamsborg G, Sorensen HA, et al. Long-term treatment with intermittent cyclical etidronate [abstract]. J Bone Miner Res. 1992;7(suppl):S177.
55. Pak CYC, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride: final report of a randomized controlled trial. Ann Intern Med. 1995;123:401-408.
56. Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet. 1997;350:550-555.
57. Riggs BL, Hodgson SF, O'Fallon WM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990; 322:802-809,
58. Wimalawansa SJ. Combined therapy with estrogen and etidronate has an additive effect on bone mineral density in the hip and vertebrae: four-year randomization study. Am J Med. 1995;99:36-42.
59. Greenspan S, Bankhurst A, Bell N, et al. Effects of alendronate and estrogen, alone or in combination, on bone mass and turnover in postmenopausal osteoporosis [abstract]. Bone. 1998;23(suppl):S174.
60. Hulley S, Grady D, Bush T, et al, for the Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
61. Looker AC, Orwoll ES, Johnston CC Jr, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res. 1997;12:1761-1768.
62. Ross PD, He Y-F, Yates AJ, et al. Body size accounts for most differences in bone density between Asian and Caucasian women. Calcif Tissue Int. 1996;59: 339-343.
63. Lindsay R, Meunier PJ, eds. Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effectiveness analysis. Osteoporos Int. 1998; 8(suppl4):S1-S88.
64. Johnston CC Jr, Miller JZ, Slemenda CW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med. 1992;327:82-87.
65. Finkelstein JS, Klibanski A, Neer RM, et al. Increases in bone density during treatment of men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1989;69:776-783.